… without shareholders' pre-emptive rights under the provisions of Article … $20 million to pursue new human therapeutics approaches based on Cellectis … ADSs will be made in Europe. Special Note Regarding Forward-Looking …
The post Cellectis Announces Launch of Follow-On Offering first appeared on TheEuropeanTimes.INFO.